Abstract
Dabigatran, a novel anticoagulant indicated for use in the treatment of venous thromboembolism, is and oral direct thrombin inhibitor with excellent pharmacodynamic characteristics which can bi given once daily, does not cuase hepatotoxicity and shows a low incidence of drug interactions. Dabigatran considerably extends therapeutic options for the prrvention of venous thromboembolism after elective knee and hip replacement surgery associated with a high risk of venous thromboembolism, incuding fatal pulmonary embolism.